Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06389019
Other study ID # BLCA_CMUFH
Secondary ID K2024-187-01
Status Recruiting
Phase
First received
Last updated
Start date January 1, 2024
Est. completion date October 1, 2024

Study information

Verified date April 2024
Source First Affiliated Hospital of Chongqing Medical University
Contact QuanHao He
Phone 800-555-5555
Email 2020120460@stu.cqmu.edu.cn
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Bladder cancer (BLCA), with its diverse histopathological features and varying patient outcomes, poses significant challenges in diagnosis and prognosis. Postoperative survival stratification based on radiomics feature and whole slide image feature may be useful for treatment decisions to improve prognosis. In this research, we aim to develop a deep learning-based prognostic-stratification system for automatic prediction of overall and cancer-specific survival in patients with BLCA.


Description:

Bladder cancer can be difficult to diagnose and predict outcomes for, as the disease can vary greatly between patients. This research aims to develop a new system that uses artificial intelligence to analyze patient information, including images from surgery and scans. This system could then automatically predict a patient's overall survival and how likely they are to survive specifically from bladder cancer. This information could be used by doctors to make better treatment decisions for each patient.


Recruitment information / eligibility

Status Recruiting
Enrollment 1000
Est. completion date October 1, 2024
Est. primary completion date June 1, 2024
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - patients with bladder cancer who had surgery like radical cystectomy or transurethral resection of bladder tumour (TURBT) - contrast-CT scan less than two weeks before surgery - complete CT image data and clinical data - complete whole slide image data Exclusion Criteria: - patients with a postoperative diagnosis of non-urothelial carcinoma - poor quality of CT images - incomplete clinical and follow-up data

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Deep learning system for prognostication prediction in bladder cancer
develop and validate a deep learning system for prognostication prediction in bladder cancer based on CT radiomics and whole slide images.

Locations

Country Name City State
China Department of Urology, The First Affiliated Hospital of Chongqing Medical University Chongqing Chongqing

Sponsors (1)

Lead Sponsor Collaborator
Mingzhao Xiao

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall survival the time from the date of surgery to death from any cause or the date of last contact (censored observation) at the date of data cut-off. up to 10 years
Secondary Recurrence free survival the time from the date of surgery to the date of first documented disease recurrence. Patients without recurrence at the time of analysis will be censored up to 10 years
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06034015 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers Phase 1
Recruiting NCT04235764 - En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
Completed NCT02371447 - VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer Phase 1/Phase 2
Recruiting NCT04081246 - Transurethral Modified En Bloc Resection For Large Bladder Tumours. N/A
Recruiting NCT06059547 - Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer Phase 2
Terminated NCT04779489 - Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer N/A
Not yet recruiting NCT04493489 - Propranolol Adjuvant Treatment of Bladder Cancer Phase 2
Completed NCT03520231 - Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases Phase 2
Recruiting NCT04537221 - Nordic Cystectomy Study III - Transfusion
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT01955408 - Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment N/A
Completed NCT04487457 - Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Recruiting NCT05562791 - A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer Phase 1
Completed NCT00199849 - NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Phase 1
Completed NCT02781428 - To Detect the Sensitivity of the UroMark Assay
Recruiting NCT04738630 - Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer Phase 2
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2
Active, not recruiting NCT03978624 - Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer Phase 2
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A